Canton Strategic Holdings, a Nasdaq-listed company, has completed the sale of its biotech research division, Gravitas Life Sciences, to Gravitas Collective Corp. The transaction, approved unanimously by the company's board, was finalized on July 17, 2026. This sale marks Canton Strategic's strategic shift towards becoming an operational enterprise focused on digitizing traditional financial markets through the Canton Network, emphasizing asset tokenization and financial infrastructure development.